Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
Rhea-AI Summary
Evotec SE (NASDAQ:EVO) has revised its revenue guidance for fiscal year 2025 while maintaining its profit outlook. The company now expects group revenues of €760-800 million, down from the previous guidance of €840-880 million. Despite lower revenue projections, Evotec maintains its adjusted EBITDA guidance of €30-50 million and R&D expenditure forecast of €40-50 million.
The guidance adjustment reflects a shift in revenue mix and successful cost-saving initiatives from the Priority Reset program. While technology licensing is showing stronger performance, the Shared R&D base business faces challenging market conditions. First-half 2025 revenues were below expectations, though adjusted EBITDA remained aligned with projections.
Positive
- Maintained adjusted EBITDA guidance of €30-50m despite revenue challenges
- Successful cost savings exceeding initial targets
- Strong performance in technology licensing segment
- H1 2025 adjusted EBITDA in line with expectations
Negative
- Reduced revenue guidance by approximately €80m
- Group revenues below expectations in H1 2025
- Challenging market environment for Shared R&D base business
- Revenue forecast shows potential decline from 2024's €797.0m
News Market Reaction – EVO
On the day this news was published, EVO declined 13.38%, reflecting a significant negative market reaction. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $234M from the company's valuation, bringing the market cap to $1.51B at that time. Trading volume was elevated at 2.8x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged.
For the current fiscal year, the Company expects Group revenues in the range of
R&D expenditures are expected in a range of
Adjusted EBITDA is expected to reach
The primary reasons for the refined guidance are a change in the revenue mix and significant cost savings in excess of initial targets set during the Priority Reset. Technology licensing - a key pillar of Evotec's strategic repositioning - is expected to make a stronger contribution. At the same time, the Shared R&D base business is expected to continue to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in H1 2025, while adjusted EBITDA was broadly in line with expectations. Actions are underway to transform the business towards sustainable profitable growth.
- End of the ad hoc release -
Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)151 1940 5058 (m), volker.braun@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire
FAQ
What is Evotec's (NASDAQ:EVO) new revenue guidance for 2025?
Has Evotec (NASDAQ:EVO) changed its EBITDA guidance for 2025?
What are the main reasons for Evotec's revenue guidance adjustment in 2025?
How did Evotec perform in H1 2025?
What is Evotec's R&D expenditure guidance for 2025?
